To continue reading this article, sign up for FREE to
Membership is FREE
and provides you with
instant access
to email newsletters, digital publications, our full content catalogue & more...
BioSeek Initiates Compound Evaluation Collaboration with GSK
BioSeek, Inc. has announced that it has entered into a collaboration agreement with GlaxoSmithKline. Under the collaboration, BioSeek will apply its BioMAP® Systems for the characterization of compounds from GSK.
BioSeek's BioMAP® Systems are a series of human primary cell-based assay systems designed to replicate the intricate cell and pathway interactions present in human disease biology.
Depending on their mechanism of action, compounds induce specific patterns of changes in these systems (BioMAP profiles) that can be compared to a large number of reference profiles in BioSeek's database.
BioMAP profiling is designed to provide in-depth characterization of drug function, including defining mechanism of action and secondary activities, and can provide insights into potential clinical applications.
"We are excited to be working closely with the innovative scientific teams in GSK as we continue to demonstrate the utility of BioMAP Systems to drive drug discovery," commented Peter Staple, chief executive officer of BioSeek.
"This collaboration will enable us to make use of the full range of applications of our technology."
